Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Advair Relaunch And Nasal Naloxone Nod Raise Hikma’s Expectations
Also Strikes Branded Injectables Deal With Melinta For MENA Region
Apr 30 2021
•
By
David Wallace
Hikma expects its generics business to hit the top end of its 2021 forecast • Source: Alamy
More from Earnings
More from Business